In addition to EGFR mutation-targeted therapy, multiple examples of genotype-directed therapy producing dramatic responses in molecular subtypes of lung cancer are emerging, including ALK rearrangements, ROS1 rearrangements, MET amplification, BRAF mutations, HER2 mutations, and RET rearrangements [63]. This evidence concerns the gene EGFR and lung carcinoma.